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Hypotension, bradycardia, pulmonary artery hypertension, neutropenia, and thrombocytopenia 
have been suspected to be due to complement activation following protamine reversal of heparin. This 
investigation examined these phenomena in complement-depleted animals. Eight dogs received intra- 
peritoneal naja n. naja cobra venom factor (CVF), 20 U/kg, 48 and 24 hr prior to anticoagulation with 
sodium heparin, 150 IU/kg, and reversal 30 min later with protamine sulfate, 1.5 mg/kg. Decomple- 
mentation was confirmed in all dogs. Systemic blood pressure (BP), pulse (HR), pulmonary artery 
systolic and diastolic pressures, (PAS, PAD), cardiac output (CO), platelet count (PTC), and white 
blood count (WBC) with differential were monitored. The maximal mean changes for the entire group 
were BP, -43 mm Hg; HR, -16; PAS, +6 mm Hg; PAD, +3 mm Hg; CO, -27%; PTC, -49%; and 
WBC, -48%. These hemodynamic and hematologic responses, occurring in the face of CVF-induced 
decomplementation, support the conclusion that complement components C3 and C5-C9 are not 
influential factors contributing to these protamine-heparin-induced events. 0 1988 Academic PW, IK. 
Protamine sulfate is a useful agent for the 
reversal of the anticoagulant effect of sodium 
heparin. However, in both animals and pa- 
tients, this drug may cause a number of un- 
desirable hemodynamic and hematologic 
adverse responses, including hypotension, 
bradycardia, pulmonary artery hypertension, 
thrombocytopenia, and neutropenia [ l-41. 
Complement activation has been suspected 
to be the cause of these responses, although a 
direct relationship between hematologic 
changes and complement activation after 
protamine administration has not been ob- 
served in prior experiments undertaken by 
the authors [2, 31. The purpose of this inves- 
tigation was to produce a state of comple- 
ment deficiency in animals utilizing cobra 
venom factor (CVF) and to quantitate sub- 
sequent responses to protamine reversal of 
heparin anticoagulation. 
MATERIALS AND METHODS 
Eight adult mongrel dogs (mean weight, 13 
kg) were treated with cobra venom factor 
from the naja n. naja cobra 48 and 24 hr 
prior to the experimental study. The venom 
was given intraperitoneally for a total dose of 
40 U/kg (20 U/kg with each administration). 
CVF was isolated from crude lyophilized 
cobra venom by ion-exchange chromatogra- 
phy and gel filtration [5]. 
The dogs were anesthetized with sodium 
pentobarbital (30 mg/kg intravenous) and 
mechanically ventilated. Anesthesia was 
maintained with supplemental sodium pen- 
tobarbital. Hydration was assured by admin- 
istration of lactated Ringers solution, 20 
cc/kg/hr. All animals had an arterial catheter 
placed in the right femoral artery, a Swan- 
Ganz catheter placed in the pulmonary ar- 
tery by way of the right femoral vein, and a 
venous catheter inserted in the left femoral 
vein. Hemodynamic measurements in- 
cluded mean systemic blood pressure (BP), 
pulse (HR), pulmonary artery systolic pres- 
sure (PAS), pulmonary artery diastolic pres- 
sure (PAD), and cardiac output (CO) using 
thermodilution technique. Hematologic 
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measurements included platelet count 
(PTC), complete blood count (CBC) with 
differential count, total hemolytic comple- 
ment (CH,,) values, and crossed immuno- 
electrophoresis for monitoring of comple- 
ment activation. 
All animals were heparinized with sodium 
heparin (150 III/kg, intravenous) and 30 
min later the heparin was reversed with prot- 
amine sulfate (1.5 mg/kg, infused intrave- 
nously over a IO-set period). These are stan- 
dard doses administered clinically at our 
medical center. The rapid protamine infu- 
sion was chosen to magnify hemodynamic 
responses. Hemodynamic measurements in- 
cluding BP, HR, PAS, and PAD were moni- 
tored continuously. CO, PTC, and CBC were 
monitored at baseline, 3 min after heparin 
administration, 3 min prior to protamine re- 
versal, and at 30 set, 1, 3, 5, 10, and 30 min 
following completion of the protamine re- 
versal. 
Thrombin clotting times revealed full anti- 
coagulation in all animals after heparin ad- 
ministration and complete reversal with ad- 
ministration of protamine sulfate. Hemato- 
logic assessments were also made before and 
after each administration of CVF. 
Complement depletion was documented 
by assaying plasma samples for total hemo- 
lytic complement activity (CHsO units), em- 
ploying a standard hemolysis test [6]. Plasma 
C3 levels were determined by crossed immu- 
noelectrophoresis procedures using a specific 
antibody against canine C3. Since the height 
of the C3 peak in the gel slab relates directly 
to the amounts of C3 present in plasma, per- 
centage changes in C3 concentrations were 
easily calculated. Data analyses included cal- 
culation of sample means with standard de- 
viations, and comparisons using a paired t 
test. Animal care complied with the Princi- 
ples of Laboratory Animal Care and the 
Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 80-23, re- 
vised 1976). 
RESULTS 
Protamine reversal of heparin produced a 
maximal fall in BP of 43 + 24 mm Hg at 150 
set with a persistent decline of 9 + 16 mm 
Hg at 30 min (Fig. 1). Statistically significant 
differences from baseline BP were noted 
from 75 to 180 set after reversal. Interest- 
ingly, two dogs showed only minimal hypo- 
tension with BP decreases of 10 and 12 mm 
Hg, respectively. The HR dropped 15 + 18 at 
135 set and 16 f 14 at 5 min (Fig. 2). Signifi- 
cant differences from baseline HR were 
found at 135 set, as well as at 5 and 10 min. 
Elevations of both systolic and diastolic 
pulmonary artery pressure occurred. The 
maximal PAS rise was 6 + 9 mm Hg at 60 set 
after protamine administration, and the 
maximal PAD rise was 3 f 6 mm Hg at this 
same time interval. These values were not 
statistically different from baseline pressures 
(Fig. 3). Finally, CO declined 27% from ini- 
tial baseline values at 180 set after protamine 
administration, although there was an initial 
rise at 30 set (Fig. 4). 
Hematologic changes were more marked. 
PTC fell 49% from initial counts at 60 set 
after protamine administration and re- 
mained 30% below baseline at 30 min (Fig. 
5). Significant PTC differences occurred at 
all time periods. Similarly, white blood cell 
counts fell 48% from baseline at 60 set fol- 
lowing protamine administration (Fig. 6). 
Full recovery of the latter was noted by 5 
FIG. 1. Mean systemic arterial blood pressure change 
after protamine reversal of heparin. 
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FIG. 2. Pulse change after protamine reversal of hep- 
arin. 
min. There was a slight decline in the per- 
centage of granulocytes, from 47 to 38% at 
30 set after protamine reversal. The percent- 
age of lymphocytes rose initially from 36 to 
47% at 30 set, and declined to 30% at 5, 10, 
and 30 min after the protamine reversal. Eo- 
sinophils accounted for 5% of the white cells 
initially, a percentage that increased to 12% 
at 60 set following protamine reversal. 
Monocyte, basophil, and stab analysis did 
not reveal any significant changes, probably 
reflecting their initial low levels of 4, 2, and 
l%, respectively. 
Baseline PTC before the first CVF admin- 
istration was 284,000 + 98,000. PTC just 
prior to protamine reversal 48 hr later was 
25 1,000 + 8 1,000, representing a slight de- 
crease of 12%. The baseline white blood cell 
count before the first CVF administration 
was 24,000 ? 19,000 and 48 hr later it had 
FiG. 3. Pulmonary artery blood pressure change (sys- 
tolic, diastolic) after protamine reversal of heparin. 
TIME FOLLOWING PROTAMINE 
REVERSAL OF HEPARIN 
FIG. 4. Cardiac output change after protamine reversal 
of heparin. 
fallen to 5000 + 3900, a decrease of 79%. 
Interestingly, the white blood cell count 24 
hr after the first CVF administration had in- 
creased 3 1% to 31,400 f 8900. 
Total hemolytic complement activity in 
plasma was 9 5.3 units before CVF treatment, 
but only 10 units after the second CVF ad- 
ministration. At the same time, there was an 
83 + 3% reduction in plasma C3 levels com- 
pared to pretreatment values. 
DISCUSSION 
Complement activation has been sug- 
gested as a cause of the adverse hemody- 
namic and hematologic effects of protamine 
sulfate [7- 131. It has been known for more 
than a decade that protamine, when added to 
l Db.05 + PS.Ol 
TIME FOLLOWING PROTAMM 
REVERSAL OF HEPPRIN 
FIG. 5. Platelet count change after protamine reversal 
of heparin. 
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FIG. 6. White blood cell count change after protamine 
reversal of heparin. 
acute phase serum, consumed the comple- 
ment cascade components Cl, C4, and C2, 
with little consumption of C3-C9, in a reac- 
tion that was dependent on time, tempera- 
ture, pH, and salt concentration, including 
the presence of calcium ions [9]. This reac- 
tion occurred even in the absence of heparin, 
as well as in normal sera with high doses of 
protamine. C-reactive protein appears to be 
the essential component in acute phase 
serum, which acts with protamine to facili- 
tate this response that has been postulated to 
begin at the level of C lq. 
Combinations of heparin and protamine, 
at levels below those causing complement 
activation if either substance is given sepa- 
rately, deplete total hemolytic complement 
in vitro [lo]. Heparin was found to be ap- 
proximately 20 times more anticomplemen- 
tary in the presence of protamine sulfate, and 
protamine was 5- 10 times more anticom- 
plementary in the presence of sodium hepa- 
r-in [lo]. Heparin, alone, minimally lowered 
C 1 and C3-C9 levels, but augmented C4 and 
C2 activity, an effect thought to be due to 
heparin’s action on antithrombin III. Prot- 
amine, alone had little effect on complement 
activation in the aforementioned study. 
However, heparin plus protamine depleted 
total hemolytic complement in the fashion of 
an antibody-antigen complex with classical 
pathway activation beginning at the level 
of Cl. 
Earlier in vitro studies were followed by in 
vivo experiments using rabbits in which gen- 
eration of C5a was implied by existance of a 
transient granulocytopenia produced by hep- 
arin-protamine interaction [ 111. This re- 
sponse was also noted to occur following 
protamine administration alone in animals 
having elevated C-reactive protein levels, al- 
beit not to a statistically significant degree. 
Depletion of complement factors with CVF 
completely abolished the granulocytopenic 
response. This indirectly supported the con- 
tention that complement, up to and includ- 
ing C5, could be activated by protamine. 
Humans undergoing cardiopulmonary 
bypass exhibited elevated C3a and C4a levels 
after protamine reversal of heparin, impli- 
cating classical pathway activation [ 121. 
These elevations were distinct from those oc- 
curring in the cardiopulmonary bypass cir- 
cuit itself. It was postulated that complement 
activation, pulmonary sequestration of leu- 
kocytes, lysosomal enzyme release, superox- 
ide generation, histamine release from mast 
cells, and finally increased capillary perme- 
ability occurred in response to protamine re- 
versal of heparin. However, it should be 
noted that the 100 patients in this study did 
not exhibit reversal hypotension and thus 
correlations of hemodynamic data to com- 
plement values were not possible. In addi- 
tion, the measurements in the aforemen- 
tioned study were obtained 10 min after 
protamine reversal, a time beyond that when 
the adverse responses have been documented 
to occur in peripheral vascular surgery pa- 
tients with protamine reversal of heparin [2]. 
Similar findings have been noted by Kirklin 
and his colleagues [ 131. 
In contrast to these two former studies, 
that both suggest complement activation as- 
sociated with heparin-protamine interac- 
tions, is a third report on humans undergo- 
ing cardiopulmonary bypass [ 141. In this 
study no consumption of complement, par- 
ticularly C3 and C4, could be documented 
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following protamine reversal of heparin anti- 
coagulation. In this regard, we were unable 
to document activation of total hemolytic 
complement with protamine reversal of hep- 
arin activity in an earlier canine study [3], 
and in a patient study no correlation existed 
between hemodynamic parameters and C3a 
generation [2]. 
In the present investigation, we chose to 
study dogs depleted of complement factors 
by treatment with CVF in an attempt to re- 
solve the controversy surrounding this topic. 
CVF is a 144,000 Da protein that works with 
a cofactor (factor B of the alternative com- 
plement pathway) to cause complement ac- 
tivation [ 15, 161. CVF interacts with factor B 
in a reversible, Mg*+-dependent complex, in 
order to be cleaved by another cofactor of the 
alternative pathway (factor D). From this in- 
teraction, factor B is cleaved to a smaller 
fragment (Ba) which is released and a larger 
fragment (Bb) which remains bound to the 
CVF. This binding is important for C3 deav- 
age and perpetuation of the alternative path- 
way. Thus, by this means CVF leads to mas- 
sive activation of the alternative complement 
cascade and decomplementation for both the 
classical and alternative pathways from C3 to 
C9. The low complement levels achieved by 
CVF may remain reduced for as long as 5 
days [ 15, 171. Decomplementation was com- 
plete in all animals of the current investiga- 
tion. 
We have previously studied the hemody- 
namic and hematologic responses in dogs to 
protamine reversal of heparin using standard 
doses as used in the current study [ 1, 3, 181. 
In complement-intact animals, the blood 
pressure typically dropped 40 mm Hg at 75 
and 120 set after reversal along with pro- 
found bradycardia of - 19 at 90 to 105 set 
postreversal. Pulmonary artery hypertension 
occurred some 90 set after reversal up to +9 
mm Hg PAS, and cardiac output diminished 
by 30% at 60 set postreversal. Platelet count 
typically fell 75%, while white blood cell 
count dropped 60% at 60 set after reversal. 
Finally, only a 7% activation of CH50 was 
noted in animals 30 set and 5 min after re- 
versal. 
Certain differences were apparent when 
comparing the results of this study to our 
earlier work. First, the typical two-phase hy- 
potensive response as noted previously did 
not occur [3]. Second, pulmonary artery 
pressure elevations occurred earlier than 
would have been expected and were slightly 
less than those reported previously [3]. 
Third, although neutropenia did develop, the 
expected granulocytopenia was not observed 
[3]. Finally, the magnitude of the thrombo- 
cytopenia was slightly less than predicted. 
[3]. A few comments regarding our under- 
standing of the events surrounding the re- 
sponses usually accompanying heparin- 
protamine reactions deserve comment. 
As mentioned, protamine-induced hypo- 
tension is typically a two-phase response 
after a IO-set rapid bolus of protamine, 
phase one being maximal at 75 set and phase 
two at 120 sec. Bradycardia and pulmonary 
artery hypertension are most marked 90 and 
105 set after reversal. Each phase may be 
mediated by different mechanisms. The first 
phase seems most likely to be due to a direct 
toxic effect of protamine on vessels or their 
cell membranes. This effect leads to vasodi- 
lation with a corresponding decrease in total 
peripheral resistance. Although thrombocy- 
topenia does develop during this first phase, 
thrombocytopenic dogs still demonstrate 
early hypotension [ 191. On the other hand, 
platelet aggregation and release of vasoactive 
substances most probably are responsible for 
phase two reactions, causing pulmonary ar- 
tery hypertension, bradycardia, and further 
hypotension [3, 201. Thrombocytopenic 
dogs do not develop bradycardia and pulmo- 
nary artery hypertension [ 191. The second 
phase may be thrombin dependent in that 
platelets subjected to protamine are inhibited 
in their aggregation to thrombin but not 
ADP [ 19, 2 1, 221. In addition, we have dem- 
onstrated that pulmonary accumulation of 
platelets can be completely blocked by prot- 
amine pretreatment in the dog [ 181. 
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Complement activation in animals and 
humans following protamine administra- 
tion appears to be a secondary event rather 
than a cause of major hemodynamic and 
hematologic changes. That adverse hemo- 
dynamic and hematologic responses to prot- 
amine occur in dogs with documented de- 
complementation supports this contention. 
Although C 1, C4, or C2 components of the 
cascade could contribute to the adverse re- 
sponses, inasmuch as these components are 
not inhibited by the CVF, it is unlikely that 
one of them is responsible for all the ob- 
served reactions without further generation 
of activated C3, CS, and the rest of the cas- 
cade. However, C2 activation is known to 
generate a kinin-like moiety, and C4a ana- 
phylatoxin exists, both of which can cause 
vasodilation and increased capillary perme- 
ability [23]. The influence of these specific 
component factors in heparin-protamine 
reactions must still be investigated. Never- 
theless, this study documents that inhibition 
of complement was not protective against 
the adverse reactions noted with protamine 
reversal of heparin activity although the 
magnitude of some of the responses was 
slightly less than previously reported from 
our laboratory in studies of this canine 
model [3]. 
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